Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul:84:106479.
doi: 10.1016/j.intimp.2020.106479. Epub 2020 Apr 27.

Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease

Md Sahab Uddin  1 , Md Tanvir Kabir  2 , Abdullah Al Mamun  3 , George E Barreto  4 , Mamunur Rashid  5 , Asma Perveen  6 , Ghulam Md Ashraf  7
Affiliations
Review

Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease

Md Sahab Uddin et al. Int Immunopharmacol. 2020 Jul.

Abstract

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases characterized by the formation of extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). Growing evidence suggested that there is an association between neuronal dysfunction and neuroinflammation (NI) in AD, coordinated by the chronic activation of astrocytes and microglial cells along with the subsequent excessive generation of the proinflammatory molecule. Therefore, a better understanding of the relationship between the nervous and immune systems is important in order to delay or avert the neurodegenerative events of AD. The inflammatory/immune pathways and the mechanisms to control these pathways may provide a novel arena to develop new drugs in order to target NI in AD. In this review, we represent the influence of cellular mediators which are involved in the NI process, with regards to the progression of AD. We also discuss the processes and the current status of multiple anti-inflammatory agents which are used in AD and have gone through or going through clinical trials. Moreover, new prospects for targeting NI in the development of AD drugs have also been highlighted.

Keywords: Alzheimer's disease; Anti-inflammatory agents; Immune system; Neuroinflammation; Proinflammatory molecules.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms